Mar. 11, 2005 — Apogee Technology Inc., a provider of silicon-based innovations for specialized applications, announced it has signed an agreement with the University of Medicine and Dentistry New Jersey’s Laboratory for Drug Delivery to conduct research and testing on the company’s MEMS-based transdermal drug delivery device.
Apogee selected the lab to study the compatibility of representative large molecule drugs with Apogee’s transdermal solution. The device is designed to be part of an alternate delivery solution for new and existing large molecule drugs currently used to treat various conditions, such as diabetes, infectious disease, acute pain and chronic pain. Completion of preliminary studies is expected by year-end, followed by the testing of Apogee’s solution for use with selected target drugs for commercialization in 2007.